Maurer, M. S., Soman, P., Hernandez, A., Garcia-Pavia, P., Signorovitch, J., Wei, L. J., Hanna, M., Ruberg, F. L., Kittleson, M., Kazi, D., Dorbala, S., Hsu, K., Lousada, I., Adigun, R., Dunnmon, P., Kelly, J., Gillmore, J., Masri, A., … Sanjurjo, V. (2024). Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings. Advances in Therapy, 41(7), 2723–2742. https://doi.org/10.1007/s12325-024-02891-0

Yang, J., Chaudhry, B. I., Yue, A. T., Roth, J. A., Kelton, J. M., Shelbaya, A., Tran, L., & Li, M. (2023). The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study. Advances in Therapy, 41(1), 349–363. https://doi.org/10.1007/s12325-023-02703-x

Jhalani, N. B. (2022). Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Advances in Therapy, 39(8), 3472–3487. https://doi.org/10.1007/s12325-022-02169-3

Askanase, A. D., & Furie, R. A. (2022). A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus. Advances in Therapy, 39(7), 3088–3103. https://doi.org/10.1007/s12325-022-02160-y

Abraham, B., Eksteen, B., Nedd, K., Kale, H., Patel, D., Stephens, J., Shelbaya, A., Chambers, R., & Soonasra, A. (2022). Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). Advances in Therapy, 39(5), 2109–2127. https://doi.org/10.1007/s12325-022-02104-6